CY1125482T1 - Παραγωγο καρβοξαμιδιου και τα διαστερεομερη του σε σταθερη κρυσταλλικη μορφη - Google Patents

Παραγωγο καρβοξαμιδιου και τα διαστερεομερη του σε σταθερη κρυσταλλικη μορφη

Info

Publication number
CY1125482T1
CY1125482T1 CY20221100554T CY221100554T CY1125482T1 CY 1125482 T1 CY1125482 T1 CY 1125482T1 CY 20221100554 T CY20221100554 T CY 20221100554T CY 221100554 T CY221100554 T CY 221100554T CY 1125482 T1 CY1125482 T1 CY 1125482T1
Authority
CY
Cyprus
Prior art keywords
diasteromers
crystalline form
stable crystalline
carboxamide derivative
diastereomers
Prior art date
Application number
CY20221100554T
Other languages
Greek (el)
English (en)
Inventor
Olli Törmäkangas
Terhi HEIKKINEN
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55349869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125482(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of CY1125482T1 publication Critical patent/CY1125482T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20221100554T 2015-01-30 2022-08-16 Παραγωγο καρβοξαμιδιου και τα διαστερεομερη του σε σταθερη κρυσταλλικη μορφη CY1125482T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20150033 2015-01-30

Publications (1)

Publication Number Publication Date
CY1125482T1 true CY1125482T1 (el) 2026-02-25

Family

ID=55349869

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100554T CY1125482T1 (el) 2015-01-30 2022-08-16 Παραγωγο καρβοξαμιδιου και τα διαστερεομερη του σε σταθερη κρυσταλλικη μορφη

Country Status (14)

Country Link
US (4) US10010530B2 (enExample)
EP (1) EP3250554B1 (enExample)
JP (2) JP7283861B2 (enExample)
CY (1) CY1125482T1 (enExample)
DK (1) DK3250554T3 (enExample)
ES (1) ES2917549T3 (enExample)
HR (1) HRP20220998T1 (enExample)
HU (1) HUE058986T2 (enExample)
LT (1) LT3250554T (enExample)
PL (1) PL3250554T3 (enExample)
PT (1) PT3250554T (enExample)
RS (1) RS63477B1 (enExample)
SI (1) SI3250554T1 (enExample)
WO (1) WO2016120530A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6716023B2 (ja) * 2016-08-26 2020-07-01 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド アンドロゲン受容体拮抗薬の結晶形及びその製造方法並びに用途
CN108218908A (zh) * 2016-12-15 2018-06-29 连云港润众制药有限公司 一种新型雄激素受体拮抗剂的制备方法
CN121181479A (zh) 2017-03-07 2025-12-23 奥赖恩公司 结晶药物产品的制备
CN110944979B (zh) * 2017-08-09 2023-05-12 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
CN107602471B (zh) * 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法
JP2021515040A (ja) * 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
WO2021001603A1 (en) 2019-07-02 2021-01-07 Orion Corporation Pharmaceutical composition of darolutamide
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
CN110452123B (zh) * 2019-08-30 2021-10-29 南京师范大学 一步构建c-c、c-n、c-s键的合成方法
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2022049075A1 (en) 2020-09-02 2022-03-10 Bend Research, Inc. Amorphous solid dispersion of darolutamide
WO2022144926A1 (en) * 2020-12-31 2022-07-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide
EP4486727B1 (en) 2022-02-28 2026-02-25 Química Sintética, S.A. Crystalline form of darolutamide
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
WO2012143599A1 (en) 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides

Also Published As

Publication number Publication date
US20190321333A1 (en) 2019-10-24
US20180008577A1 (en) 2018-01-11
US10376494B2 (en) 2019-08-13
JP2018503662A (ja) 2018-02-08
HUE058986T2 (hu) 2022-09-28
DK3250554T3 (da) 2022-06-27
US10835515B2 (en) 2020-11-17
US20180280354A1 (en) 2018-10-04
US10010530B2 (en) 2018-07-03
JP7283861B2 (ja) 2023-05-30
US10383853B2 (en) 2019-08-20
SI3250554T1 (sl) 2022-09-30
EP3250554A1 (en) 2017-12-06
WO2016120530A1 (en) 2016-08-04
ES2917549T3 (es) 2022-07-08
PL3250554T3 (pl) 2022-09-19
HRP20220998T1 (hr) 2022-11-11
LT3250554T (lt) 2022-06-10
PT3250554T (pt) 2022-06-02
RS63477B1 (sr) 2022-08-31
EP3250554B1 (en) 2022-05-18
JP2021020935A (ja) 2021-02-18
US20180280355A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
CY1125482T1 (el) Παραγωγο καρβοξαμιδιου και τα διαστερεομερη του σε σταθερη κρυσταλλικη μορφη
CY1125230T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CL2019000397A1 (es) Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491)
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
CY1124913T1 (el) Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
EA202091500A1 (ru) Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
HUE054379T2 (hu) Helyettesített indolin-származékok mint a dengue vírus szaporodásának inhibitorai
CY1120273T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση φαρνεσοειδων υποδοχεων χ
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
HUE055577T2 (hu) Helyettesített indolin-származékok mint a dengue vírus szaporodásának inhibitorai
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
EP3431075A4 (en) EDARAVONDARREICHUNGSFORM
JO3581B1 (ar) مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي
IL269657A (en) Transduced indulin derivatives as inhibitors of dengue virus replication
IL270726A (en) Transduced indulin derivatives as inhibitors of dengue virus replication
SI3601266T1 (sl) Substituirani derivati indolina kot zaviralci replikacije virusa denga
MX2015009855A (es) Nuevos compuestos sustituidos con halogeno.
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
JO3155B1 (ar) معدِّل نكهة حلوة
CY1125352T1 (el) Κρυσταλλικες ενωσεις
SG11202101751XA (en) 5 to 7 membered heterocyclic amides as jak inhibitors
EA201692037A1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
EA201790046A1 (ru) Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης